Browsing by Author "Kuru E."
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Evaluation of Emotional Adverse Effects of Antidepressants: A Follow-up Study(Lippincott Williams and Wilkins, 2020) Asçibasi K.; Çökmüs F.P.; Dikici D.S.; Özkan H.M.; Alçi D.; Altunsoy N.; Kuru E.; Yüzeren S.; Aydemir Ö.Purpose/Background Emotional adverse effects due to antidepressant use may cause difficulties for the clinician in the treatment of depression. In this prospective study, the emotional adverse effects of antidepressants were evaluated in various aspects. Methods/Procedures Ninety eight patients diagnosed with major depressive disorder were included in the study. At 2nd, 4th, 8th, 12th, and 16th weeks, patients were assessed with Montgomery-Asberg Depression Rating Scale (MADRS), and the antidepressant dose was increased in patients with less than a 50% reduction at each visit compared with the initial MADRS score. The Oxford Questionnaire on the Emotional Side-effects of Antidepressants (OQESA) was used at the 8th-week and 16th-week visits. Findings/Results A significant difference is found in the OQESA score at the 8th-week visit compared with the 16th-week assessment (P < 0.001, t = 5.73). There were significant correlations between MADRS scores and OQESA scores both at the 8th (r = 0.346, P = 0.05) and the 16th (r = 0.490, P < 0.001) weeks. In regression analyses, at eighth-week assessment, MADRS score (B = 1.487, P = 0.002) and selective serotonin reuptake inhibitor use (B = 14.014, P = 0.023) had a significantly predicted OQESA score. Implications/Conclusions In this study, it is found that, as the rate of remitted patients is increased, OQESA scores get decreased, and furthermore, the OQESA score of the remitted group is statistically low when compared with that of the nonremitted group at the 8th- and 16th-week visits. Oxford Questionnaire on the Emotional Side-effects of Antidepressants and MADRS scores are significantly correlated in all assessments. These results suggest that the score obtained from OQESA may be related not only to the emotional adverse effects of antidepressants but also to the residual symptoms of depression. © Wolters Kluwer Health, Inc. All rights reserved.Item Evaluation of psychosocial functioning in the acute treatment term of major depressive disorder: A 16-week multi-centered follow-up study(Elsevier B.V., 2021) Altunsoy N.; Di̇ki̇ci̇ D.S.; Çökmüş F.P.; Özkan H.M.; Aşçibaşi K.; Alçi D.; Kuru E.; Yüzeren S.; Aydemi̇r Ö.Objective: Major depressive disorder is the leading cause of non-fatal burden, and disability in adulthood. Even though depression is well-treated in the acute term,psychosocial functioning does not get back to the premorbid level most of the time. In this present study, it is aimed to evaluate the outcome of the acute term treatment of major depressive disorder in terms of psychosocial functioning. Methods: The study is an open-label, observational, multi-center follow-up study for four months of patients with major depressive disorder according to DSM-5. Patients were evaluated with Montgomery Asberg Depression Rating Scale (MADRS), Sheehan Disability Scale (SDS) and Short Form-36 (SF-36) at the beginning, and at the 2., 4., 8., 12. and 16.weeks. Results: 100 patients were invited to the study and 56 patients completed the study.As a result of the treatment, the mean MADRS and SDS scores decreased significantly. All domains of SF-36 were improved significantly with the treatment. Unfortunately patients suffering from MDD could not reach the normative data,especially on the domains of social functioning, role emotional, pain, and general health perception. Treatment outcomes show that SNRI users presented higher scores on the domains of pain and physical functioning. However SSRI users showed better outcomes on the domains of mental health and vitality. Conclusion: Our research corroborated that even patients gain symptomatic remission in MDD treatment, psychosocial dysfunction persists. It is also concluded that different antidepressant options may act differently on treatment outcomes. © 2021 Elsevier B.V.Item The Assessment of Cognitive Dysfunction in Major Depressive Disorder: A 16-Week Prospective Case-Control Study(AVES, 2021) Poyraz Çökmüş F.; Murat Özkan H.; Sücüllüoğlu-Dikici D.; Aşçibaşi K.; Alçi D.; Altunsoy N.; Kuru E.; Yüzeren S.; Aydemir Ö.Objective: Cognitive dysfunction is one of the core components of major depressive disorder (MDD). It is estimated that two-thirds of patients diagnosed with MDD have cognitive deficits. Cognitive symptoms are pervasive and affect functioning in several domains. This 16-week prospective case-control study aimed to assess the change of mood and cognitive symptoms during treatment. Materials and Methods: Ninety-eight patients with MDD and 113 healthy controls (HCs) participated in the study. The MDD group was evaluated 6 times (baseline, 2nd, 4th, 8th, 12th, and 16th weeks). For mood symptoms, the Montgomery-Asberg Depression Rating Scale was used, and for neurocognitive functions, the Perceived Deficits Questionnaire-Depression was used, and the Digit Symbol Substitution Test was administered to both groups. Results: At baseline, compared with the HCs, the neurocognitive function of patients with MDD was worse. From the 8th to the 16th week assessments, in both neurocognitive tests, the cognitive functions of patients with MDD had improved. Despite this improvement and the patients achieving remission, the patients’ cognitive performance did not improve to the level of the HC group at the 16th week. Conclusion: Our longitudinal research revealed that even though mood symptoms decreased and patients with depression did achieve symptomatic remission, their cognitive deficits perpetuated. © 2020, AVES. All rights reserved.